MAGEA4 and synovial sarcoma: ,212,213 Specifically, treatment with autologous T cells with an affinity-optimized T cell receptor against MAGE-A4 (afamitresgene autoleucel or afami-cel) resulted in an overall response rate of 24% in patients with 9 different relapsed/refractory metastatic solid tumor types, with the highest clinical activity in synovial sarcoma (overall response rate of 44%).212